[Perception of physicians on factors that influence the choice of a dicoumarin or a new oral anticoagulant in patients with non-valvular atrial fibrillation].

CONCLUSIONS: The presence of a high thrombotic or haemorrhagic risk and the failure of previous dicoumarin therapy lead to choosing a new oral anticoagulant in patients with non-valvular atrial fibrillation, while kidney failure, cognitive impairment, good control with dicoumarins, and a low bleeding risk predispose to selecting a classic dicoumarin anticoagulant. PMID: 26971361 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/26971361?dopt=Abstract

Source: Atencion Primaria - March 10, 2016 Category: Primary Care Authors: Anguita-Sánchez M, Marco-Vera P, Alonso-Moreno FJ, Arribas-Ynsaurriaga F, Gállego-Culleré J, Honorato-Pérez J, Suárez-Fernández C, Investigadores del estudio ACADEMIC Tags: Aten Primaria Source Type: research